Is Revolution Medicines (RVMD) The Best Biotech Stock According to Billionaire Stanley Druckenmiller?

Druckenmiller's Stake: $30,717,000

Revolution Medicines (NASDAQ:RVMD) is simply a biotech institution processing targeted crab drugs.

Revolution Medicines (NASDAQ:RVMD) precocious reported a Phase 3 triumph for its pb cause daraxonrasib. The results showed the campaigner cause chopped the hazard of decease by astir 60% and much than doubled endurance successful patients with precocious pancreatic crab compared to chemotherapy.

Additional Phase 3 programs see adjuvant PDAC settings aft country and perioperative therapy, arsenic good arsenic enlargement into non-small compartment lung crab (NSCLC), widening the full accidental beyond pancreatic crab alone.

Revolution Medicines (NASDAQ:RVMD) is besides processing zoldonrasib, a selective RAS G12D inhibitor, with plans for aggregate Phase 3 combinations. This creates a 2nd maturation motor targeting a high-frequency mutation successful pancreatic and lung cancers.

Some besides judge Revolution Medicines (NASDAQ:RVMD) could go an acquisition people for ample pharma looking to deepen their oncology pipelines.

Aristotle Growth Equity Fund stated the pursuing regarding Revolution Medicines, Inc. (NASDAQ:RVMD) successful its fourth 4th 2025 capitalist letter:

"Revolution Medicines, Inc. (NASDAQ:RVMD) is simply a institution focused connected processing caller treatments for cancer, specifically for patients whose cancers are driven by changes successful RAS proteins. Their probe and improvement is centered connected creating drugs called RAS(ON) inhibitors, which purpose to artifact the maturation signals from these proteins. The company's main drugs—Daraxonrasib, Elironrasib, and Zoldonrasib—are already being tested successful objective trials. Revolution Medicines is moving connected bringing a caller drug, RMC-5127, into trials soon. In addition, the institution is processing much targeted treatments for different types of RAS mutations.

We spot Revolution arsenic presenting a compelling concern lawsuit driven by the robust objective show of its pb candidate, Daraxonrasib (RMD-6236), presently successful signifier 3 trials for precocious non-small compartment lung crab (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). The cause has demonstrated awesome efficacy successful hard-to-treat cancers, with precocious nonsubjective effect and illness power rates, importantly outperforming existing modular treatments. Daraxonrasib's U.S. Food and Drug Administration (FDA) Breakthrough Therapy Designation and inclusion successful the FDA Commissioner's National Priority Review Voucher programme item its committedness and imaginable for accelerated approval. With ongoing enlargement into earlier lines of therapy and aggregate operation studies successful coagulated tumors, arsenic good arsenic a pipeline of further agents successful development, Revolution is good positioned for aboriginal maturation and worth instauration successful the oncology space. As a clinical-stage biotechnology company, valuation tin beryllium challenging fixed nary commercialized products. Sell-side analysts person projected that Daraxonrasib's PDAC-only gross could scope respective cardinal dollars by the mid-2030s. This would effect successful a existent worth that is conscionable implicit 1 times imaginable highest revenue, which is little than the aggregate typically seen successful humanities biotech merger & acquisition transactions (Click Here to Read the Letter successful Detail)."